Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study

Khitam Muhsen*, Nimrod Maimon, Ami Mizrahi, Omri Bodenheimer, Dani Cohen, Michal Maimon, Itamar Grotto, Ron Dagan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: We assessed vaccine effectiveness (VE) of BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) acquisition among healthcare workers (HCWs) of long-Term care facilities (LTCFs). Methods: This prospective study, in the framework of the "Senior Shield"program in Israel, included routine weekly nasopharyngeal SARS-CoV-2 RT-PCR testing from all LTCF HCWs since July 2020. All residents and 75% of HCWs were immunized between December 2020 and January 2021. The analysis was limited to HCWs adhering to routine testing. Fully vaccinated (14+ days after second dose; n=6960) and unvaccinated (n=2202) HCWs were simultaneously followed until SARS-CoV-2 acquisition or end of follow-up, 11 April 2021. Hazard ratios (HRs) for vaccination versus no vaccination were calculated (Cox proportional hazards regression models, adjusting for sociodemographics and residential-Area COVID-19 incidence). VE was calculated as (1-HR)×100. RT-PCR cycle threshold (Ct) values were compared between vaccinated and unvaccinated HCWs. Results: At >14 days post-second dose, 40 vaccinated HCWs acquired SARS-CoV-2 (median follow-up, 66 days; cumulative incidence, 0.6%) versus 84 unvaccinated HCWs (median follow-up, 43 days; cumulative incidence, 5.1%) (HR .11; 95% CI,. 07-.17; unadjusted VE 89%; 95% CI, 83-93%). Adjusted VE >7 and >14 days post-second dose were similar. The median PCR Ct targeting the ORF1ab gene among 20 vaccinated and 40 unvaccinated HCWs was 32.0 versus 26.7, respectively (P value =.008). Conclusions: VE following 2 doses of BNT162b2 against SARS-CoV-2 acquisition in LTCF HCWs was high. The lower viral loads among SARS-CoV-2-positive HCWs suggest further reduction in transmission.

Original languageEnglish
Pages (from-to)E755-E763
JournalClinical Infectious Diseases
Volume75
Issue number1
DOIs
StatePublished - 1 Jul 2022

Keywords

  • BNT162b2 vaccine
  • SARS-CoV-2 infection
  • effectiveness
  • healthcare workers
  • long-Term care facilities

Fingerprint

Dive into the research topics of 'Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study'. Together they form a unique fingerprint.

Cite this